1. Good Distribution Practice of Human and Veterinary Medicinal Products and Medical Devices

2. Overview Introduction (page 1) Scope (page 2)
Quality Management (page 3)
Personnel (page 14)
Premises and Equipment (page 19)
Documentation (page 28)
Operations
Complaints, Returns, suspected falsified Medicinal Products and Medicinal Product Recalls
Contract Operations
Self Inspection
Transportation
Brokers

3. Introduction
Distribution is an important activity in the integrated supply-chain management of pharmaceutical product. Numerous people and entities are responsible for the handling, storage and distribution of such products. In some cases, a specific person or entity is responsible only for specific elements of the distribution process.
The objective of this presentation is to assist in ensuring the quality and identity of Pharmaceutical product in the storage and distribution process is maintained.

4. Scope
This training applies to the procuring, storage, sale and distribution of pharmaceutical and veterinary medicines and medical devices.
The training covers controls to be applied in ensuring the product Quality, Safety and Efficacy is not compromised during the supply chain handling of product.
Note: Distribution of starting materials is not covered in this training.

5. Quality Management (1) Quality System
Organisation
Structure
Policy
Procedure
Process
Resource

6. Quality Management (2) Quality System
A Responsible Person (RP) must be appointed at each distribution site with direct contact with company Managing Director
The RP is suitably qualified with a number of years working knowledge of pharmaceutical storage, distribution and Quality.

7. Quality Management (3) Quality System
The RP should have a defined authority and responsibility in ensuring that a quality system is implemented and maintained
The Quality System must be adequately resourced with competent personnel, suitable premises, equipment and facilities
All quality activities to be well defined in procedures and their effectiveness monitored
A quality Manual or equivalent should be established
A change control system should be in place to manage critical process changes. This system should be part of the risk management programme.

8. Quality Management (4) Quality System
Ensure….
Products are procured, stored and supplied or exported in accordance with the requirements of GDP
Clearly defined management responsibilities
Product delivered to correct recipient and within the agreed time period
Quality related activities are documented at the time they are performed.

9. Quality Management (4) Quality System
Deviations from procedures are documented and investigated within a defined time period
CAPA system is in place to correct deviations and prevent them in line with principles of Quality Risk Management .

10. Quality Management (5) Management of Outsourced Activities
To control and review the outsourced activity, the Quality Risk Management programme should be followed. This will include:
Assessing authorisation status, suitability and competence of contractor prior to outsourcing services
Defining in a Quality Agreement the responsibilities and communication process for quality related activities between involved parties
Monitoring and reviewing outsourced services and implementing any improvements required on an ongoing basis.

11. Quality Management (6) Management Review and Monitoring
Periodic senior management review of QMS to include assessment of:
Complaints
Deviations
Recalls
CAPA
Change Control
Self inspection and regulatory audits
External audits
Risk assessments

12. Quality Management (7) Management Review and Monitoring
Continued….
Regulation updates – likely to impact company QMS
Innovations to enhance company QMS
Changes in Company strategy
Note: This list is not exhaustive
Senior management reviews should be performed at least annually. Must be effectively documented and communicated to all applicable parties.

13. Quality Management (8) Quality Risk Management (QRM)
A systematic process for:
Assessment
Control
Communication
And review of the risk to the quality of product
Can be applied both proactively or retrospectively
Evaluation is based on scientific knowledge and experience with the process and product
The greater the risk the greater the amount of information required for assessing the risk (documentation commensurate with level of risk)
Further information on the application of QRM can be found in ICH Q9.

14. Personnel The Responsible Person (RP) for GDP (1)
Every Distribution company must have a permanently available RP
They should meet the conditions provided for by the legislations of the member state concerned in relation to qualification and experience
Must be able to demonstrate that wholesale distributor is in compliance with GDP and public service obligations are met

15. Personnel The Responsible Person (RP) for GDP (2)
Responsibilities include and are not limited to:
QMS implemented and maintained
Focus on authorised activities and accuracy and quality of records
Approval of initial and continual training programme for all personnel involved in distribution activities
Coordinate and perform effectively the recall of product
Timely investigation and closure of complaints
Qualification and approval of suppliers and customers
Authorising the return to saleable stock on any returns
Approving GDP technical agreements in relation to storage and transportation
Self inspections effectively managed and documented with follow up on corrective actions
Involved in the decision on product disposition
Any product specific requirements imposed by national law are adhered to.

16. Personnel Other Personnel for GDP
Adequate number of personnel to ensure quality of product is maintained
Organisational structure detailed in an organogram to show all personnel responsibilities
Personnel roles and responsibilities detailed in a job description with any delegation of duties clearly documented.

17. Personnel Training
All personnel involved in wholesale distribution must receive formal documented initial and ongoing training that is job specific and on general GDP
This should include aspects of product identification and avoidance of falsified medicines entering the supply chain
Training should be based on written procedures and training programmes
The RP should maintain their continued professional development to fulfil their RP obligations
A record of all personnel training should be maintained and effectiveness of training should be periodically assessed and documented.

18. Hygiene
There should be procedures relating to health, hygiene and clothing. Initial and ongoing training on these procedures should be provided to all employees
Storage of food, drinks, smoking materials or medication for personal use must be prohibited in storage areas

19. Premises and Equipment Premises (1)
The Premises to be designed to ensure:
good storage conditions are maintained
Suitably secure
Structurally sound
Sufficient capacity to allow safe storage and handling of product
Adequate lighting to allow safe and accurate operations
Segregated areas for products;
to clearly define products for sale, return, reject, disposal and recalled products
Physical segregation to ensure defective products are not reintroduced into the supply chain.

20. Premises and Equipment Premises (2)
Storage areas are within defined temperature, and humidity conditions
Qualified system for monitoring storage temperature and humidity
Safety and security of any hazardous or potent products
Goods In and despatch bays should protect product from harsh weather conditions
Adequate separation between receipt, despatch and storage areas
Reception area where delivery is received and examined to be designated and suitably equipped.

21. Premises and Equipment Premises (3)
Authorised access only through appropriate access control. Site security to include, and not limited to, intruder alarm, CCTV, security patrol, perimeter ring fence and security controlled entry exit gates
Storage facilities are clean and free from litter and dust. Cleaning procedures and records should be in place and appropriate cleaning equipment should be sourced
Protection against the entry of insects, rodents or other animals. A preventative pest control programme should be in place
Rest, wash and refreshment rooms for personnel should be adequately separated from the storage areas
Agreement to be implemented with any contracted premises and ensure site has wholesale distribution authorisation prior to commencement of service.

22. Premises and Equipment Temperature and Environment Control
Suitable equipment and procedures should be in place to ensure adequate control of the storage area environment. The factors to be considered include, and are not limited to, temperature, humidity and cleanliness of the premises
Storage areas should be temperature mapped, taking into account any seasonal variations
Any initial mapping must be performed before use of the storage area
The mapping exercise should be whenever significant changes are made to the facility or temperature controlling/monitoring system. Risk assess any potential changes prior to making the change
Temperature monitoring equipment should be located according to the results of the mapping exercise.

23. Premises and Equipment Equipment (1)
All critical equipment, vital to the functionality of operations, should be on a planned preventative maintenance programme
Equipment used to control or monitor product environment should be calibrated at regular intervals
Calibrations should be traceable to a primary standard
Alarm levels should be appropriately set to alert when there is a deviation from pre-defined storage conditions. Alarms should be regularly checked to ensure they are functioning correctly.

24. Premises and Equipment Equipment (2)
Records of calibration, maintenance and repair should be maintained for the equipment listed below:
Refrigerators
Thermo hygrometers
Cold stores
Temperature and humidity recording devices
Air handling devices
And any equipment utilised in conjunction within the onward supply chain.

25. Premises and Equipment Computerised Systems (1)
Should achieve the desired results
Documentation on the computerised system:
Scope
Principles
Objectives
Security measures
Main features
How it is used and how it interacts with other systems

26. Premises and Equipment Computerised Systems (2)
Data entry and amendments by authorised personnel
Data should be secured by physical and electronic means. Stored data should be checked for:
Accessibility
Durability
Accuracy
Data should be backed up at regular intervals and stored for a period stated by national legislations
A back up procedure should be in place in the event of system failure.

27. Premises and Equipment Qualification and Validation
Q&V of key aspects of wholesale distribution activities
The scope and extent should be determined by a documented risk assessment
Validation should be planned and specify acceptance criteria
Systems should be validated and revalidated after any significant changes. E.g. expansion of cold storage
Validation report should be prepared and any deviations and CAPAs to be detailed in report. Report to be approved by appropriate personnel
Re-qualification of equipment, after repair/maintenance should be decided utilising a risk based approach.

28. Documentation (1) Part of the QMS Clearly written documents:
Policies
Procedures
Instructions
Records and Data (paper or electronic form)
Personnel should have access to the procedures and instructions applicable to their job role.

29. Documentation (2) Documentation should be:
Clear and unambiguous and easily understood by personnel
Approved, signed and dated by authorised personnel and should not be hand written
Signed and dated for any alterations made and should permit the reading of the original text. Where possible the reason for alteration should also be stated
Readily available and retained for a minimum of five (5) years or for a period stated in national legislations.

30. Documentation (3)
Valid and approved and managed by authorised personnel to ensure document system is effectively managed and controlled
Reviewed regularly, version controlled with details of changes for each revision
Superseded versions archived and all copies replaced with current version

31. Documentation (4)
Records should be retained in hard copy or electronic format
Records should include, and not limited to:
Date
Name of product
Quantity received
Supplied or brokered
Name and address of supplier
Broker or consignee
Batch number where required
Records should be completed at time of operation being performed so that any significant activities or events are traceable.

32. Operations
Ensure the product identity is not lost and the product is handled in accordance with the marketing authorisation
The supplier of all products sourced should be known to minimise the risk of Falsified products entering the legal supply chain
If distributor intends to import a product, for which they do not hold the MA (marketing authorisation), they must first notify the MA holder and the competent authority in the member state of their intention to import into that market. This process of notification should be defined in a procedure.

33. Operations - Qualification of Suppliers (1)
They must hold a Wholesale Distribution Authorisation or a Manufacturing Authorisation
They must comply with this training
They must have written procedures for critical distribution activities. eg. complaints, recalls, returns, verification and other areas covered by this training
They must be audited using questionnaires and site visits prior to the service commencing
An audit report must be completed and will form part of the risk based approach of supply selection.

34. Operations - Qualification of Suppliers (2)
If product is obtained through a broker, check that the are appropriately authorised to supply product and comply with the requirements of this training.

35. Operations - Qualification of Customer (1)
They must have authorisation to supply product to the public in the member state concerned. The checks performed should be documented
These checks and periodic re-checks may include and are not limited to:
Requesting copies of customer’s authorisation
Verifying status on an authority website
Requesting evidence of qualification or entitlement according to national legislation
Monitor transactions and investigate any irregularities in sale patterns to avoid diversion of product and risks of misuse.

36. Operations - Marketing Authorisation (MA)
If a wholesale distributor is supplying, or intending to supply product to a member state other than the member state in which the MA was granted, they should make available copy(ies) of the MA to the national competent authority of the market in which they intend to supply
Where applicable the competent authority will inform the wholesale distributor of the obligations imposed for operating on their territory.

37. Operations - Receipt of Goods
If product is received into warehouse in Europe from a third country, for the purpose of placing product in the EU market, they must possess a Manufacturer’s Importation Authorisation (MIA)
Procedures in place to detail checks performed on Goods Receipt.
Checks performed to ensure Quality of Product received:
Received from approved supplier
Correct product and quantity
If temperature controlled product, temperature logger data downloaded to observe any temperature excursions during transit
Free from damage
If product suspected to be counterfeit, to be immediately segregated and reported to local competent authority and marketing authorisation holder.

38. Operations - Storage Conditions for storage of medicinal products
Protected from the harmful effects of light, temperature and moisture
Outer packaging and pallets cleaned before storage in warehouse
Various categories of product appropriately sealed to prevent cross- contamination
Clear segregation of products in quarantine, released, rejected, returned or recalled products and those suspected to be counterfeit products
Stock rotation based on expiry date of product
Handled with care to prevent spillage, breakage or cross contamination. Minimise risk by not storing product directly on floor.
Through regular checks any products not suitable for sale to be immediately segregated from saleable stock (physically and electronically)
Stock inventories to be performed at defined periods using a risk based approach. Any discrepancies to be investigated and documented.

39. Operations – Segregation of Goods
There should be a system in place with written procedures to allow for the segregation from harmful products (rejects, returns, toxic. counterfeits).
These products should be clearly labeled with access to only authorised personnel
If segregation only performed electronically then system to be risk assessed to ensure it will provide security and it is appropriately validated before electronic segregation is implemented.
Segregated areas to be clearly defined and referenced in the applicable procedures.

40. Operations - Destruction of Obsolete Goods
Products for destruction to be handled separately and stored separate for saleable stock
Written procedure should detail how these products should be handled
Destruction should be in accordance with national and international requirements for disposal
Records of all disposed products should be maintained and destruction witnessed for any controlled drug substances
A technical agreement should be in place between the distribution warehouse and the destruction company.

41. Operations - Picking and Packing
When picking:
Procedure should be in place to ensure the correct product is picked
Ensure minimum shelf life of product as agreed with customers and detailed in a procedure
Should follow the FEFO rotation of stock
When packing:
Ensure packaging materials used will protect product from any likely damage and maintain it’s storage conditions (e.g. temperature) during transit
Seal the container in which the product is packed to avoid contamination

42. Operations - Delivery When Delivering:
Ensure the customer receiving the product is appropriately authorised/licensed to receive medicinal product
Following information to be provided on delivery note to customer:
Delivery date
Product name
Form
Batch number
Quantity
Any safety handling instructions
Transport and storage conditions
Name and address of supplier and consignee
Temperature data or temperature loggers for temperature sensitive products - to observe any adverse temperature conditions during transit

43. Operations - Export
An exporter of medicinal products must hold a wholesale dealer licence or a manufacturing authorisation
The export of medicines for wholesale distribution should follow these training guidelines with the following exceptions:
The product does not need to have a Marketing Authorisation (MA) in Europe or in the member states
The customer does not need to hold a distribution authorisation
Any products imported from a third country for export, where the imported product does not have a MA in the country of origin, the supplier does not need to hold a wholesale distribution authorisation, however they may be required to hold a specials licence subject to local regulatory requirements
If the product is exported to a person in a third country where they are entitled (licensed) to supply products to public then the requirements of this training would apply.

44. Complaints, Returns, Suspected Falsified Medicinal Products and Medicinal Product Recalls
All complaints potentially concerning medicinal product defects must be reviewed carefully in appropriate timescales to minimise any risk to patient safety
An assessment must be performed on all returns before deciding on product disposition
A good relationship must exist between partners within the supply chain to prevent entry of falsified medicines
A system must be in place for an effective recall of product and this system must be challenged periodically
Procedures must be in place to detail how complaints, returns, falsified medicines and recalls will be managed.

45. Complaints There should be:
A written procedure on how to handle complaints on product Quality defects and those relating to distribution. The MA holder should be notified of any Quality/Safety related complaints promptly
A person/ department responsible for handling complaints
A system of documenting and investigating all complaints. The national competent authority should be notified promptly of any justified complaints
Where applicable, follow up action should be taken after investigation and evaluation of complaint.

46. Returned Medicinal Products (1)
There should be:
A written procedure on handling and acceptance of returned medicinal products
A segregated area for returns. Returns should be kept in this area until a decision is taken regarding the disposition of product
Stock should only be returned to saleable stock if all of the below requirements are met:
The MA holder does not accept returns
Secondary packaging is un-opened and not damaged, and in good condition
The customer returning product must return within five days of original dispatch if they do not hold a wholesale distribution authorisation

47. Returned Medicinal Products (2)
Sufficient documentation/data exists to show the product has been transported, stored and handled under specified conditions
The documentation/data has been reviewed and assessed by an appropriately trained, competent, authorised person. This person should certify that the conditions, in which the product was stored and handled, were in compliance with GDP
Distributor has supporting documentation, including original delivery note, to confirm the customer to whom the product was supplied, batch and expiry details, and to satisfy themselves that the product returned has not been falsified
For cold chain products, there must be supporting temperature data to show product stability has not been compromised when outside the control of the distributor.

48. Returned Medicinal Products (3)
The MA holder has assessed the packaging components to ensure they are the regulatory approved artwork
The return to saleable stock or for disposal should be approved by the Responsible Person and this should be documented
Any stock returned to saleable stock should be placed back into the FEFO system

49. Suspected Falsified Medicinal Products
There should be:
Procedures in place on how to handle suspect or confirmed falsified medicinal products, and on informing the MA holder and the competent authority
Initial and ongoing GDP training for staff to raise the awareness of the risk of falsified medicinal products entering the supply chain
Physical and secure segregation of falsified medicines from legitimate stock and a stock inventory maintained.

50. Medicinal Product Recalls
Procedure required for Management of recalls; this should be periodically challenged and effectiveness reviewed
A system for actioning recall from market promptly
Distributor should follow instructions from MA holder and should ensure where applicable, that the competent authority has given approval for recall to commence
Records available for recall activities performed and should be made available to the competent authorities
All records relating to the distribution of product should be made available to the person(s) responsible for initiating the recall. This should also include details of all customers who were supplied the recalled product. Details of batch, expiry and Quantity
A segregated and secure location for recalled products while awaiting a decision on disposition
The progress of the recall should be documented and a final report issued. This should include a reconciliation between the delivered and recovered quantities of the recalled product.

51. Contract Operations
When outsourcing GDP related activities, a Technical Agreement/ Quality Agreement should exist between the Contract Giver and Contract Acceptor.
The agreement should cover all wholesale distribution activities and clearly detail both party duties and responsibilities.
Both parties must hold a distribution authorisation or appropriately certified by a competent regulatory authority.

52. Contract Operations – Contract Giver
Responsible for the activities contracted out.
Assesses the contract acceptor through audits and other means to ensure that principles and guidelines of GDP are followed.
Audits of contract acceptor should be performed before service commences and thereafter on a periodic basis.
Should provide the contract acceptor with the information necessary to carry out the contracted service in accordance with the specific product and regulatory requirements.

53. Contract Operations – Contract Acceptor
Should have adequate premises, equipment, knowledge, experience and competent personnel to perform the contracted service
Where wholesale distribution activities are performed, the contract acceptor is subject to all obligations detailed in their wholesale distribution licence.
Should not contract out any services to a third party without an initial assessment eg. Audit, and prior approval from the Contract Giver. A written agreement should exist between the Contract Acceptor and third party in relation to GDP activities.
Informs Contract Giver of incidences or complaints, relating to the Contract Giver’s Product, within agreed reporting times defined in agreement.

54. Contract Operations – Quality Agreement/Technical Agreement - Contents
Typical agreement contents for wholesale storage and distribution
Country licensing requirements
Customer/client verification
Receipt of Product
Storage of Product
Transportation
Incidents
Returns
Complaints and falsified medicines (relating to product quality and safety)
Recalls
Audits and inspections
Sub-contracting
Contact details
Date of review
Signatures
(This list is not exhaustive and can vary depending on the type of GDP service provided)

55. Self Inspections
A self-inspection programme should be implemented to cover all aspects of GDP on site to ensure compliance with regulations, guidelines and SOPs
Should be performed by competent person(s) from the company. Audits can also be performed by an independent consultant, however they must be accompanied by a competent person from the company
Subcontractors should be part of the self inspection audit programme. These audits should be tracked on a schedule and performed on a periodic basis
Should be documented in an audit report with observations detailing deficiencies in breach of GDP guidelines. This report is to be shared with company senior management.
Corrections of deficiencies should be managed through a CAPA process.

56. Transportation(1)
It is the responsibility of the wholesale distributor to ensure the transport conditions, through adequate precautionary measures are maintained so as to protect the product from any damage, contamination, theft or exposure to adverse temperature.
Products should be transported in accordance with the storage conditions detailed on the secondary packaging
A risk assessment should be performed when selecting a method of transportation. This is to ensure the quality of the product is not adversely affected whilst on transit
Transportation conditions should be appropriately validated

57. Transportation(2) Requirements for transportation:
Transport within pre-defined limits and in accordance with product storage conditions
Deviations should be immediately communicated to the distributor to decide on the fate of the transported product. Where necessary, the manufacturer of the product should also be contacted to assess quality of affected product
Delivery drivers, including contractors should be trained in GDP applicable to their duties
SOPs should be in place for the operation and maintenance of vehicles and equipment used in the distribution process including their cleaning and safety. Cleaning detergents should be carefully selected to prevent contamination of medicinal product
Temperature monitoring systems, in vehicles and/or containers should be appropriately validated, maintained and calibrated at regular intervals
Dedicated vehicles and equipment should be used where possible when handling medicinal products. Where dedicated vehicles or equipment are not used, SOPs should be in place to detail effective controls to be used.

58. Transportation(3) Requirements for transportation:
Medicinal products should only be delivered to the address on the delivery note and must be handed into the care of the consignee
In case of emergency deliveries outside of normal hours, an SOP must be in place to detail how these deliveries will be made
If transportation is provided by a third party, then a technical agreement must be in place to detail GDP activities applicable to transportation (see slides 51 to 54)
If transportation hubs are utilised, medicinal products should be stored for no longer than 24 hours at hub whilst awaiting onward transportation. If products are stored for greater than 24 hours then hub would require a wholesale dealer licence. If cold chain products are stored at hub for any length of time, then storage hub will require a wholesale dealer licence.
Intermediate storage facilities where product is unloaded and loaded, eg. terminals and hubs, need to be audited. In particular, temperature monitoring, pest control, cleanliness, stock segregation and security.

59. Containers, Packaging and Labelling
Ensure the following are used:
Containers that are free from contamination
Containers that protect from external contamination
Containers and packaging should be of the right dimensions to securely hold product and to provide some protection from extreme external temperatures. Packaging and shipment containers to be validated for extended transit times and temperature extremes
Container labels should have information on the contents, supplier and storage and handling precautions for product.

60. Transportation of Products Requiring Special Conditions
For deliveries or narcotics or psychotropic substances, the distributor must maintain a safe and secure supply chain and must adhere to the requirements laid down by the concerned member state
Additional controls must be in place for delivery of these products with procedures on security and handling of product theft
Highly active and radioactive products should be transported in secure containers by dedicated vehicles to ensure product and handling personnel are safe from harm
Any safety measures applied must be in accordance with national and international legislations.

61. Temperature Control During Transport
Temperature-sensitive products must be transported in vehicles that are temperature controlled. The refrigeration system in the vehicle should be validated and temperature mapped for seasonal variations to ensure the temperature is maintained within pre-defined limits for full or partial load throughout the year. A printout of the temperature in the vehicle during transit should be provided to the recipient of the product.
Where vehicles are not temperature controlled, products should be packaged in thermal packaging/temperature controlled containers which should be validated. When validating, extreme conditions should be taken into consideration to ensure product quality is not affected where there is a deviation from the ideal delivery conditions
Temperature loggers should be packaged with product during transportation. The loggers should be reviewed by product recipient to ensure that the product was transported within the specified temperature range
In the event of a temperature excursion (eg.vehicle breakdown) this needs to be documented in a Deviation Report and investigated to identify root cause and prevention measures. The process of handling such deviations should be detailed in an SOP .
All temperature monitoring devices must be frequently serviced, callibrated, and challenged
When packing product with cool packs in container, ensure product does not come in contact with cool pack as this can damage the product. Staff must be trained against an SOP on how to pack products with cool-packs, assembly of boxes (seasonal configurations) and on how cool packs can be re-used.

62. Specific Provisions for Brokers (1)
Are people who negotiate independently and on behalf of their customer for the sale or purchase of medicinal product
Are subject to a competent authority registration and must have a permanent address and contact details in the union under which they are registered
Must notify the competent authority immediately of any changes in relation to sale or purchase of medicinal product
Do not procure, supply or hold medicines therefore principles or directive 2001/83 EC on premises, installations and equipments do not apply. However principles that apply to wholesale distribution do apply. In particular maintenance of a QMS that ensures records are kept; emergency plans for supporting recalls are in place; and competent authorities are immediately informed of any suspect falsified medicines offered in the supply chain.

63. Specific Provisions for Brokers (2)
Quality System:
Should consist of a number of written procedures which should be reviewed and kept up to date. The procedure should cover responsibilities, processes and risk management
Personnel:
Anyone involved in Brokering must be trained in the applicable EU and national legislations, GDP guidelines applicable to brokerage and on the issues concerning falsified medicinal products.
Documentation:
General provisions on documentation would apply (slide 28 to 32)
Following procedures required as a minimum
Complaints handling
Informing competent authority and MA holder of suspected falsified medicinal products
Supporting recalls
Ensuring products brokered have a Marketing Authorisation
Verification of suppliers to ensure they hold the appropriate licence and this is checked periodically
Records of any transactions of medicinal products brokered should contain the minimum information
Date; name of medicinal product; quantity brokered; name and address of the supplier and the customer; batch number and expiry of the medicinal product.

64. Thank You
Any Questions?